Keywords: aranesp, negative, survival, impact, sclc, biotechnology, giant

Aranesp has no negative survival impact in SCLC

Article | 17 September 2007

Print This

US biotechnology giant Amgen says that the results from a Phase III study evaluating the safety and efficacy of Aranesp ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in